PAREXEL International Corporation (PRXL)
-NasdaqGS 46.71 
0.12(0.26%) 18 May 04:00 SGT|After Hours
:
46.71 0.00 (0.00%) 18 May 04:32 SGT
| Prev Close: | 46.83 |
|---|
| Open: | 47.08 |
|---|
| Bid: | 42.50 x 900 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 44.14 |
|---|
| Beta: | 1.31 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 46.50 - 47.18 |
|---|
| 52wk Range: | 25.12 - 47.23 |
|---|
| Volume: | 551,978 |
|---|
| Avg Vol (3m): | 521,241 |
|---|
| Market Cap: | 2.66B |
|---|
| P/E (ttm): | 33.39 |
|---|
| EPS (ttm): | 1.40 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Cramer: This Fresh-Faced IPO Still a Buyat CNBC(Tue, 14 May)
- Is PAREXEL International a Cash Machine?at Motley Fool(Mon, 13 May)
- PAREXEL INTERNATIONAL CORP FinancialsEDGAR Online Financials(Sat, 11 May)
- Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOsInvestor's Business Daily(Fri, 10 May)
- Quintiles IPO Cleans Up As New Issues Multiplyat Investor's Business Daily(Thu, 9 May)
- Pharmaceutical services provider Quintiles surges on first day of tradingat theflyonthewall.com(Thu, 9 May)
- Quintiles, PennyMac, Cyan Lead Large IPO Packat Investor's Business Daily(Tue, 7 May)
- PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, 6 May)
- Charles River Misses Estimates in 1QZacks(Fri, 3 May)
- Stocks In Give-Back Mode; Spirit Air Flies, MasterCard Offat Investor's Business Daily(Thu, 2 May)
Key Statistics
| Forward P/E (1 yr): | 24.20 |
|---|
| P/S (ttm): | 1.60 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | 1.62 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.43 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | 1.49 |
|---|
Business Summary
PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and med...
View More